Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 418 for:    mesothelioma

Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02300883
Recruitment Status : Active, not recruiting
First Posted : November 25, 2014
Last Update Posted : November 6, 2017
Sponsor:
Information provided by (Responsible Party):
Armando Santoro, MD, Istituto Clinico Humanitas

Brief Summary:

This is an observational prospective analysis of biological characteristics of malignant mesothelioma (MM) patients. Frozen and paraffin-embedded tumor specimens and pleural effusion of patients will be collected and than will be analyzed with the following analyses:

1Purification of Tumour Associated Macrophages (TAM) and tumour cells from pleural effusions.

2.Mass spectrometry analysis of TAMs and tumor cells 3.Co focal microscopy analysis of macrophages, tumour cells and specimens derived from patients.


Condition or disease
Malignant Mesothelioma

Detailed Description:

This is an observational prospective analysis of biological characteristics of malignant pleural mesothelioma (MPM) patients. Frozen and paraffin-embedded tumor specimens and pleural effusion of patients will be collected and than will be analyzed with the following analyses:

  1. Purification of TAMs and tumour cells from pleural effusions. Pleural effusions will be subjected to centrifugation in order to separate cellular and non-cellular components. Cell-free supernatant will be collected and subjected to further analysis for the identification and characterization of secreted proteins (ELISA, Western Blot). Pleural effusion cell components will be characterized by cytofluorimetry in order to evaluate leukocytes composition (e.g. macrophages, neutrophils, lymphocytes). Next, to isolate TAMs from the cellular components, the investigators will adopt a standard protocol currently performed in the investigators group to purify TAMs from ascites derived from ovarian carcinoma patients . Briefly, TAMs will be separated by their selective capacity to adhere in culture plates in serum-free conditions. After 1 hour of incubation, non-adherent cells (mainly tumour cells and other inflammatory cells) will be thoroughly washed off with jets of medium. After adherence, cells were rested for 1 hour in standard culture conditions and subsequently lysed to extract proteins. To isolate tumour cells from leukocytes, a cell sorting-based approach will be used. Briefly, inflammatory cells will be stained with lymphocyte common antigen (CD45) antibody and negative cells (tumour cells) will be separated by cell sorting. Next tumour cells will be grown and amplified in standard culture conditions.
  2. Mass spectrometry analysis of TAMs and tumor cells Generation of proteome and the phospho-proteomic maps of TAMs and tumour cells will be accomplished by quantitation of both the entire proteome and the phospho-proteome. Results obtained with TAMs will be compared to untreated, M1 and M2 polarized Monocytes-derived macrophages (M-DM), while tumor cells purified from patients' pleural effusion will be analysed with respect to human mesothelial cells. Protein samples obtained from the purified TAMs and tumour cells, derived from the patient's pleural effusions, will be extracted using lysis/acetone precipitation. Cell extracts will be subsequently subjected to trypsin digestion and the resulting peptides will be labelled with the "iTRAQ" reagents. Labelled peptides will be separated with the first dimension of the separation being strong cation exchange (SCX) chromatography. Fractions will be collected and phospho-enriched, when required. The pooled mixture of peptides will be submitted to a second dimension chromatographic separation, organized as a two-step process: a desalting/concentrating pre-column, and an analytical column for the separation. System is a nano-flow configuration, with direct interfacing to a mass spectrometer. Tandem mass spectrometry will be performed on a hybrid ion-trap (IT) - Fourier transform ion-cyclotron-resonance mass spectrometer. Quantitative and identification data analysis will be carried out with Proteome Discoverer software (Thermo), using SEQUEST as the search engine. Statistical analysis and data classification will be carried out with aid of in-house written script for the freeware statistical analysis package.
  3. Co focal microscopy analysis of macrophages, tumour cells and specimens derived from patients. The analysis will be conducted on the cellular components derived from pleural effusion (as previously described) and from frozen and paraffin-embedded tissues. Immunofluorescence staining will be performed with markers of DNA damage and polarized inflammation. Furthermore, immunofluorescence analysis will be held to validate putative new MM molecular markers obtained from the mass spectrometry studies.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Diagnostic and Prognostic Role of New Inflammation Biomarkers in Patients With Malignant Pleural Mesothelioma
Study Start Date : April 2011
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma

Group/Cohort
no treatment
no treatment



Primary Outcome Measures :
  1. dissect the molecular mechanisms underlying the development of malignant mesothelioma [ Time Frame: 24 months ]
    characterization of the microenvironment (expression of M1 and M2 markers of polarized inflammation - cytokines and chemokines inducers or inhibitors of the inflammatory response) and the interplay between tumour cells and TAMs (expression of DNA damage markers) in order to dissect the molecular mechanisms underlying the development of malignant mesothelioma


Secondary Outcome Measures :
  1. study of the effect of TAMs [ Time Frame: 24 months ]
    the study of the effect of TAMs on the induction of the DNA damage on (Human mast cell) HMC cells, and a possible synergic effect with asbestos fibers;

  2. investigation of molecular mechanisms linking macrophages [ Time Frame: 24 months ]
    the investigation of molecular mechanisms linking macrophages polarized activation with asbestos-induced mesothelioma

  3. molecular characterization (proteome) of TAMs and tumor cells [ Time Frame: 24 months ]
    the molecular characterization (proteome) of TAMs and tumor cells, isolated from pleural effusion derived from patients

  4. compare in specimens from mesothelioma patients and the candidate molecular markers [ Time Frame: 24 months ]
    to compare in specimens from mesothelioma patients and the candidate molecular markers, obtained expression in the above-mentioned tasks

  5. Investigate the association of selected markers with Overall Survival [ Time Frame: 24 months ]
    To Investigate the association of selected markers with Overall Survival (OS)


Biospecimen Retention:   Samples Without DNA
pleural effusion


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Malignant pleural mesothelioma patients
Criteria

Inclusion Criteria:

  • Malignant pleural mesothelioma patients
  • Availability of plural effusion and frozen and paraffin-embedded tumor specimens.

Exclusion Criteria:

  • Unavailability of plural effusion and frozen and paraffin-embedded tumor specimens.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02300883


Locations
Layout table for location information
Italy
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089
Istituto Clinico Humanitas
Rozzano, Milan, Italy, 20089
Sponsors and Collaborators
Armando Santoro, MD
Investigators
Layout table for investigator information
Principal Investigator: armando Santoro, MD Istituto Clinico Humanitas

Layout table for additonal information
Responsible Party: Armando Santoro, MD, Principal Investigator, Istituto Clinico Humanitas
ClinicalTrials.gov Identifier: NCT02300883     History of Changes
Other Study ID Numbers: ONC/OSS-02/2011
First Posted: November 25, 2014    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: not planned

Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial